Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel

Molecular Carcinogenesis

Volumn 50, Issue 10, 2011, Pages 811-823

  Chang, Horng Rong ^a,b   Chen, Pei Ni ^b   Yang, Shun Fa ^b   Sun, Ying Sui ^b   Wu, Sheng Wen ^a,b   Hung, Tung Wei ^a,b   Lian, Jong Da ^a   Chu, Shu Chen ^c   Hsieh, Yih Shou ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

MMP; Renal cell carcinoma; Silibinin; TIMP 2; U PA

Indexed keywords

EVEROLIMUS; FLUOROURACIL; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; SILIBININ; UROKINASE; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROURACIL; HEK293 CELLS; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PACLITAXEL; SILYMARIN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 80052296632     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20756     Document Type: Article

References (42)

1. Hutson TE. Renal cell carcinoma: diagnosis and treatment, 1994-2003. Proc Bayl Univ Med Cent 2005; 18: 337-340.
2. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-186.
3. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
5. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007; 356: 185-187.
6. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008; 15: 3954-3966.
7. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-319.
8. Herrmann E, Bierer S, Wülfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 2010; 28: 303-309.
9. Ljungberg B, Cowan NC, Hanbury D, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406.
10. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62: 3063-3069.
11. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006; 45: 436-442.
12. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997; 89: 556-566.
13. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002; 101: 461-468.
14. Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, Lu KH. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 2007; 28: 977-987.
15. Tyagi A, Raina K, Singh RP, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007; 6: 3248-3255.
16. Mohan S, Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 2004; 320: 183-189.
17. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8: 3512-3519.
18. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999; 59: 622-632.
19. Agarwal C, Singh RP, Dhanalakshmi F, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22: 8271-8282.
20. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999; 20: 2101-2108.
21. Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984; 6: 655-661.
22. Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 1992; 30: 134-138.
23. Ljungberg B, Hanbury DC, Kuczyk MA. et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510.
24. Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170: 1141-1145.
25. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40: 143-149.
26. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res 2006; 85: 220-225.
27. Chu SC, Yang SF, Liu SJ, Kuo WH, Chang YZ, Hsieh YS. In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells. Food Chem Toxicol 2007; 45: 1194-1201.
28. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
29. Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 2005; 156: 141-150.
30. Kawata N, Nagane Y, Hirakata H, et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 2007; 69: 1049-1053.
31. Takahashi M, Oka N, Naroda T, et al. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 2002; 9: 531-538.
32. Harada K, Sakai I, Ishimura T, Inoue TA, Hara I, Miyake H. Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: comparative study between incidentally detected and symptomatic diseases. Urol Oncol 2006; 24: 201-206.
33. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001; 7: 3113-3119.
34. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78: 392-487.
35. Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004; 214: 171-179.
36. Shang D, Ito N, Watanabe J, et al. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity. Eur Urol 2007; 52: 1131-1139.
37. Moriya F, Ogasawara S, Basaki Y, et al. Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo. Int J Oncol 2008; 33: 647-655.
38. Shang D, Ito N, Kamoto T, Ogawa O. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology 2007; 69: 1007-1012.
39. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 2004; 10: 794-801.
40. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 39-42.
41. Sato H, Senba H, Virgona N, et al. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 2007; 46: 215-224.
42. May M, Helke C, Bock M, Hoschke B. Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil. Urologe A 2004; 43: 1111-1119.